January 27th 2023
Vial will be supporting RecensMedical with the phase 3 clinical trial for its Ocu-Cool system.
Several strategies exist to improve safety of injections for patients.
January 26th 2023
According to the company, it is planning to hold an end-of-phase 2 meeting with the FDA to discuss the results.
January 13th 2023
Viridian Therapeutics unveils positive data from its ongoing Phase 1/2 trial evaluating low dose VRDN-001 in patients diagnosed with TED.
December 17th 2022
Rishi Singh, MD, of Cleveland Clinic Florida, touches upon the various advancements that are making a difference for clinicians and patients and reducing their progression in this disease state.
Poll results: Do you believe biosimilars have the same efficacy as branded medications?
Results from our recent poll indicate a mixed bag of responses from ophthalmologists.
Alcon completes acquisition of Aerie Pharmaceuticals
The deal adds pharmaceutical research and development capabilities and further expertise for future product pipeline. It also expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category.
BLOG: Being the change we want to see in ophthalmology
A recent study showed that only 6% of practicing ophthalmologists in the US identify as an underrepresented minority.
Targeting VEGF: The future is now
Ophthalmologists have learned to optimize their use of traditional anti-VEGF therapies and are now incorporating newer therapies like brolucizumab for managing retinal diseases, and in the not-so-distant future they can look forward to gaining familiarity with faricimab and using a new delivery system for ranibizumab.
Viatris making ophthalmology push with acquisition of Oyster Point Pharma
Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its uniquely talented team, the strength of Tyrvaya nasal spray and its ophthalmology pipeline.
EYP-1901: A look at DAVIO and PAVIA clinical trial updates
Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.
Survey: Awareness of biosimilars for retinal diseases in the US and Europe
The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.
Mont Blanc Phase 3 glaucoma trial for NCX 470 achieves primary objective
Nicox reports that daily dosing of NCX 470 0.1% met the primary efficacy objective of demonstrating non-inferiority to latanoprost 0.005%.
Immunogenicity profiles similar in neovascular AMD for ranibizumab and biosimilar drug
This post-hoc analysis was performed to evaluate immunogenicity over the long term.
Novel MIGS stent technology boasts robust IOP-lowering effect in open-angle glaucoma
First-in-human biologic stent in ophthalmology is a conforming implant material, i.e., a soft, scleral wall compliant bio-tissue to structurally reinforce the cyclodialysis cleft opening.
Study: Comparing biosimilar of ranibizumab and Lucentis in efficacy and safety for wet AMD
The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.
Spotlight on GA: A bright future with potential treatments
According to Rishi P. Singh, MD, family history and lifestyle are key in the development of geographic atrophy.
Aflibercept shown to work at higher dose, longer intervals
Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
FDA approves ranibizumab-eqrn as a biosimilar product interchangeable with ranibizumab injection for all five indications
Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.
Controlling glaucoma: Eye drop therapy reaches posterior ocular tissues
A novel eye drop under development may provide neuroprotection to the retinal ganglion cells.
Apellis announces FDA accepts NDA for pegcetacoplan
According to the company, pegcetacoplan is an investigational, targeted C3 therapy for the treatment of geographic atrophy secondary to age-related macular degeneration.
Blog: Artificial tear therapy for dry eye disease not quite as simple as it seems
Cynthia Matossian, MD, FACS, ABES, explains why eye care professionals should oversee the selection and use of artificial tears for patients with dry eye.
Two-year data confirms faricimab improves vision for patients diagnosed with wet-AMD
In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.
Kala Pharmaceuticals completes sale of Eysuvis, Inveltys to Alcon Inc.
Kala Pharmaceuticals Inc. announced that it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was first announced in May.
Eyelid ptosis case treated with brimonidine 0.33% gel
Researchers believe this may be the first report of the use of topical brimonidine gel for the treatment of eyelid ptosis associated with cosmetic use of botulinum toxin.
Intracanalicular insert linked to reduced hyperemia and itching
As dexamethasone adds indications, a study confirms efficacy of punctal occlusion for allergic conjunctivitis.
Dry eye disease associated with Sjögren’s syndrome: Cost of treatment a factor
In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.
Aurion Biotech raises $120 million to fund its cell therapy efforts
Aurion noted that its first candidate is a cell therapy for the treatment of corneal edema secondary to endothelial dysfunction.
Tarsus announces positive topline data of TP-03 from Saturn-2 Phase 3 trial, expects to file NDA later this year
TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events. 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure.
UCI-led study lays foundation for establishing base editing as a one-time, durable treatment for inherited retinal degeneration
According to researchers at the University of California, Irvine, base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis patients.
Allergan announces positive topline Phase 3 results for presbyopia therapeutic
According to the company, the VIRGO trial evaluated the safety and efficacy of the investigational twice-daily administration of pilocarpine HCl ophthalmic solution 1.25% in adults with presbyopia. The trial met its primary efficacy endpoint, the company noted.
Novartis: European Commission approves brolucizumab 6 mg for patients with diabetic macular edema
Approval is based on year 1 data from the Phase III KESTREL and KITE trials investigating brolucizumab 6 mg versus aflibercept 2 mg in DME patients.
Presbyopia Awareness Month: Importance, treatment options
April is Presbyopia Awareness Month. Brieann K. Adair, OD, of NYU Langone Health, speaks with Ophthalmology Times’ Sheryl Stevenson about the importance of Presbyopia awareness, treatment options and more.
Outlook Therapeutics submits Biologics License Application to FDA for ONS-5010 as a treatment for Wet AMD
If the BLA is approved, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.
Study: UPLIZNA effective for people with newly presenting neuromyelitis optica spectrum disorder
A separate analysis will be presented at the American Academy of Neurology 2022 Annual Meeting, showing that UPLIZNA reduced pan associated with NMOSD over 3 years.
2 Clarke Drive Cranbury, NJ 08512